[1] Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease – A systematic review and meta-analysis[J]. PLoS One, 2016, 11(7): e0158765.
[2] Lin CN, Wu IW, Huang YF, et al. Measuring serum total and free indoxyl sulfate and p-cresyl sulfate in chronic kidney disease using UPLC-MS/MS[J]. J. Food Drug Anal, 2019, 27(2): 502–509.
[3] Holle J, Kirchner M, Okun J, et al. Serum indoxyl sulfate concentrations associate with progression of chronic kidney disease in children[J]. PLoS One, 2020, 15(10): e0240446.
[4] Cheng TH, Ma MC, Liao MT, et al. Indoxyl sulfate, a tubular toxin, contributes to the development of chronic kidney disease[J]. Toxins, 2020, 12(11): 684.
[5] Li X, Lu Z, Zhou F, et al. Indoxyl sulfate promotes the atherosclerosis through up-regulating the miR-34a expression in endothelial cells and vascular smooth muscle cells in vitro[J]. Vasc. Pharmacol, 2020, 131: 106763.
[6] Zhang H, Chen J, Shen Z, et al. Indoxyl sulfate accelerates vascular smooth muscle cell calcification via microRNA-29b dependent regulation of Wnt/β-catenin signaling[J]. Toxicol. Lett, 2018, 284: 29–36.
[7] Six I, Flissi N, Lenglet G, et al. Uremic toxins and vascular dysfunction[J]. Toxins, 2020, 12(6): 404.
[8] LIN YT, WU PH, LIANG SS, et al. Protein-bound uremic toxins are associated with cognitive function among patients undergoing maintenance hemodialysis[J]. Sci. Rep, 2019, 9(1): 20388.
[9] Liu WC, Wu CC, Lim PS, et al. Effect of uremic toxin-indoxyl sulfate on the skeletal system[J]. Clin. Chim. Acta, 2018, 484: 197–206.
[10] Van Der Made TK, Fedecostante M, Scotcher D, et al. Quantitative translation of microfluidic transporter in vitro data to in vivo reveals impaired albumin-facilitated indoxyl sulfate secretion in chronic kidney disease[J]. Mol. Pharm, 2019, 16(11): 4551–4562.
[11] Nishi K, Sakurama K, Watanabe H, et al. Effects of uremic toxins on the binding of aripiprazole to human serum albumin[J]. Biol. Pharm. Bull, 2021, 44(3): 437–441.
[12] Smith J, Pfaendtner J. Elucidating the molecular interactions between uremic toxins and the sudlow II binding site of human serum albumin[J]. J. Phys. Chem. B, Am. Chem. Soc, 2020, 124(19): 3922–3930.
[13] Shi Y, Tian H, Wang Y, et al. Effect of Ionic strength, pH and chemical displacers on the percentage protein binding of protein-bound uremic toxins[J]. Blood Purif, 2019, 47(4): 351–360.
[14] Tao X, Thijssen S, Kotanko P, et al. Improved dialytic removal of protein-bound uraemic toxins with use of albumin binding competitors: an in vitro human whole blood study[J]. Sci. Rep, 2016, 6(1): 23389.
[15] Madero M, Cano KB, Campos I, et al. Removal of protein-bound uremic toxins during hemodialysis using a binding competitor[J]. Clin. J. Am. Soc. Nephrol, 2019, 14(3): 394–402.
[16] Maheshwari V, Thijssen S, Tao X, et al. In silico comparison of protein-bound uremic toxin removal by hemodialysis, hemodiafiltration, membrane adsorption, and binding competition[J]. Sci. Rep, 2019, 9(1): 909.
[17] Hy?pler R, Tichá A, ?afránek R, et al. Indoxyl sulfate elimination in renal replacement therapy: Influence of Citrate- versus acetate-buffering component during bicarbonate dialysis[J]. Dis. Markers, 2018, 2018: 1–7.
[18] Yamamoto S, Sasahara K, Domon M, et al. pH-dependent protein binding properties of uremic toxins in vitro[J]. Toxins, 2021, 13(2): 116.
[19] Yen SC, Liu ZW, Juang RS, et al. Carbon nanotube/conducting polymer hybrid nanofibers as novel organic bioelectronic interfaces for efficient removal of protein-bound uremic toxins[J]. ACS Appl. Mater. Interfaces, 2019, 11(47): 43843–43856.
[20] 彭海萍, 吴广礼. 不同血液净化方法对维持性血液透析患者毒素清除力的影响分析[J]. 中华全科医学, 2020, 18(05): 757-759+800.
[21] Gomó?ka M, Niemczyk L, Szamotulska K, et al. Protein-bound solute clearance during hemodialysis[J]. Adv. Exp. Med. Biol , 2019,1153: 69–77.
[22] Heri? T, Vivoda T, Bogataj ?, et al. Medium cut-off dialysis membrane and dietary fiber effects on inflammation and protein-bound uremic toxins: a systematic review and protocol for an interventional study[J]. Toxins, 2021, 13(4): 244.
[23] 刘书馨, 肖佳, 单婧, 等. 不同血液透析方式对大鼠体内硫酸吲哚酚清除影响的研究[J]. 中国血液净化, 2020, 19(11): 760–763.
[24] REDERT Study Group, Panichi V, Rocchetti M T, et al. Long term variation of serum levels of uremic toxins in patients treated by post-dilution high volume on-line hemodiafiltration in comparison to standard low-flux bicarbonate dialysis: results from the REDERT study[J]. J. Nephrol, 2017, 30(4): 583–591.
[25] Thammathiwat T, Tiranathanagul K, Limjariyakul M, et al. Super high‐flux hemodialysis provides comparable effectiveness with high‐volume postdilution online hemodiafiltration in removing protein‐bound and middle‐molecule uremic toxins: A prospective cross‐over randomized controlled trial[J]. Ther. Apheresis Dial, 2021, 25(1): 73–81.
[26] Paats J, Adoberg A, Arund J, et al. Serum levels and removal by haemodialysis and haemodiafiltration of tryptophan-derived uremic toxins in ESKD patients[J]. Int. J. Mol. Sci, 2020, 21(4): 1522.
[27] Murtas S, Aquilani R, Deiana ML, et al. Differences in amino acid loss between high-efficiency hemodialysis and postdilution and predilution hemodiafiltration using high convection volume exchange—a new metabolic scenario? A pilot study[J]. J. Renal Nutr, 2019, 29(2): 126–135.
[28] Oh WC, Mafrici B, Rigby M, et al. Micronutrient and amino acid losses during renal replacement therapy for acute kidney injury[J]. Kidney Int. Rep, 2019, 4(8): 1094–1108.
[29] Li J, Han L, Liu S, et al. Removal of indoxyl sulfate by water-soluble poly-cyclodextrins in dialysis[J]. Colloids Surf, B, 2018, 164: 406–413.
[30] Pavlenko D, Giasafaki D, Charalambopoulou G, et al. Carbon adsorbents with dual porosity for efficient removal of uemic toxins and cytokines from human plasma[J]. Sci. Rep, 2017, 7(1): 14914.
[31] Sternkopf M, Thor?e-Boveleth S, Beck T, et al. A bifunctional adsorber particle for the removal of hydrophobic uremic toxins from whole blood of renal failure patients[J]. Toxins, 2019, 11(7): 389.
[32] Shi Y, Wang Y, Ma S, et al. Increasing the removal of protein‐bound uremic toxins by liposome‐supported hemodialysis[J]. Artif. Organs, 2019, 43(5): 490–503.
[33] Shi Y, Tian H, Wang Y, et al. Removal of protein-bound uremic toxins by liposome-supported peritoneal dialysis[J]. Peritoneal Dial. Int, 2019, 39(6): 509–518.
[34] Shen Y, Wang Y, Shi Y, et al. Improving the clearance of protein-bound uremic toxins using cationic liposomes as an adsorbent in dialysate[J]. Colloids Surf, B, 2020, 186: 110725.
[35] Lu L, Yeow JTW. An adsorption study of indoxyl sulfate by zeolites and polyethersulfone–zeolite composite membranes[J]. Mater. Des, 2017, 120: 328–335.
[36] Raharjo Y, Fahmi MZ, Wafiroh S, et al. Incorporation of imprinted-zeolite to polyethersulfone/cellulose acetate membrane for creatinine removal in hemodialysis treatment[J]. J. Teknol, 2019, 81(3): 137-144.
[37] Sasaki M, Liu Y, Ebara M. Zeolite composite nanofiber mesh for indoxyl sulfate adsorption toward wearable blood purification devices[J]. Fibers, 2021, 9(6): 37.
[38] Gryp T, De Paepe K, Vanholder R, et al. Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease[J]. Kidney Int ,2020, 97(6): 1230–1242.
